CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
2020 · Cancer Immunology Immunotherapy · 27 citations
https://doi.org/10.1007/s00262-020-02742-1
T
Takahiro Aoki
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
139
Papers
918
Citations
17
h-index
26
i10-index
Takahiro Aoki is an academic researcher from National Center for Global Health and Medicine. The author has contributed to research in topics: Immune Cell Function and Interaction & CAR-T cell therapy research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 17, co-authored 119 publications.
ORCID: 0000-0002-9148-2871Papers by this author
worksFIGURE 3 from Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner
2024 · 0 citations
https://doi.org/10.1158/2767-9764.25245030.v1
FIGURE 7 from Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner
2024 · 0 citations
https://doi.org/10.1158/2767-9764.25245018
FIGURE 3 from Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner
2024 · 0 citations
https://doi.org/10.1158/2767-9764.25245030
FIGURE 7 from Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner
2024 · 0 citations
https://doi.org/10.1158/2767-9764.25245018.v1
FIGURE 8 from Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner
2024 · 0 citations
https://doi.org/10.1158/2767-9764.25245015
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat